Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chih-Jen Yang

Showing results (151-160 of 191) with videos related to

Pageof 20
Sort By:
Cancers|January 8, 2023
Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical OutcomesChia-Yu Kuo, Ming-Ju Tsai, Jen-Yu Hung, et al.
Translational Oncology|August 19, 2022
The aberrant cancer metabolic gene carbohydrate sulfotransferase 11 promotes non-small cell lung cancer cell metastasis via dysregulation of ceruloplasmin and intracellular iron balanceWei-Min Chang, Li-Jie Li, I-An Chiu, et al.
Cancer Research|September 25, 2012
Adenylate kinase-4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor ATF3Yi-Hua Jan, Hong-Yuan Tsai, Chih-Jen Yang, et al.
BMJ Open|March 21, 2023
Role of single-dose intravenous iron therapy for the treatment of anaemia after orthopaedic trauma: protocol for a pilot randomised controlled trialDanielle F Peterson, Natasha S McKibben, Catherine E Hutchison, et al.
Anticancer Research|January 30, 2026
First-Line Afatinib 30 mg <i>Versus</i> 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in TaiwanHui-Yang Hung, Tai-Huang Lee, Cheng-Hao Chuang, et al.
Journal of Clinical Medicine|October 13, 2021
First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-AnalysisKuan-Li Wu, Hsiao-Ling Chen, Ying-Ming Tsai, et al.
Journal of Clinical Medicine|June 24, 2022
Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-AnalysisTai-Huang Lee, Hsiao-Ling Chen, Hsiu-Mei Chang, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2025
Pharmacological effects of small molecule BCR-ABL tyrosine kinase inhibitors on platelet functionYiheng Zhang, Chih-Jen Yang, Alexander R Melrose, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 8, 2024
<b>Pharmacological effects of small molecule BCR-ABL tyrosine kinase inhibitors on platelet </b>Yiheng Zhang, Chih-Jen Yang, Alexander R Melrose, et al.
Journal of Medicinal Food|February 9, 2010
Antiproliferative and antitumorigenic activity of Toona sinensis leaf extracts in lung adenocarcinomaChih-Jen Yang, Yu-Jung Huang, Cheng-Yuan Wang, et al.
Pageof 20

Showing results (151-160 of 191) with videos related to

Sort By:
Pageof 20
Cancers|January 8, 2023
Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical OutcomesChia-Yu Kuo, Ming-Ju Tsai, Jen-Yu Hung, et al.
Translational Oncology|August 19, 2022
The aberrant cancer metabolic gene carbohydrate sulfotransferase 11 promotes non-small cell lung cancer cell metastasis via dysregulation of ceruloplasmin and intracellular iron balanceWei-Min Chang, Li-Jie Li, I-An Chiu, et al.
Cancer Research|September 25, 2012
Adenylate kinase-4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor ATF3Yi-Hua Jan, Hong-Yuan Tsai, Chih-Jen Yang, et al.
BMJ Open|March 21, 2023
Role of single-dose intravenous iron therapy for the treatment of anaemia after orthopaedic trauma: protocol for a pilot randomised controlled trialDanielle F Peterson, Natasha S McKibben, Catherine E Hutchison, et al.
Anticancer Research|January 30, 2026
First-Line Afatinib 30 mg <i>Versus</i> 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in TaiwanHui-Yang Hung, Tai-Huang Lee, Cheng-Hao Chuang, et al.
Journal of Clinical Medicine|October 13, 2021
First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-AnalysisKuan-Li Wu, Hsiao-Ling Chen, Ying-Ming Tsai, et al.
Journal of Clinical Medicine|June 24, 2022
Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-AnalysisTai-Huang Lee, Hsiao-Ling Chen, Hsiu-Mei Chang, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2025
Pharmacological effects of small molecule BCR-ABL tyrosine kinase inhibitors on platelet functionYiheng Zhang, Chih-Jen Yang, Alexander R Melrose, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 8, 2024
<b>Pharmacological effects of small molecule BCR-ABL tyrosine kinase inhibitors on platelet </b>Yiheng Zhang, Chih-Jen Yang, Alexander R Melrose, et al.
Journal of Medicinal Food|February 9, 2010
Antiproliferative and antitumorigenic activity of Toona sinensis leaf extracts in lung adenocarcinomaChih-Jen Yang, Yu-Jung Huang, Cheng-Yuan Wang, et al.
Pageof 20